Skip to content

Postoperative pain reduction following umbilical hernia repair

Elective Umbilical Hernia Repair: Outcomes of postoperative Pain in Adults after local Wound Infiltration or ultrasound-guided bilateral REctus Sheath block. (EUHROPA WIRES trial)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27010
Enrollment
66
Registered
2016-06-03
Start date
2016-05-23
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

umbilical hernia postoperative pain rectus sheath block

Interventions

ultrasound guided bilateral rectus sheath block local wound infiltration.

Sponsors

maxima medical centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult (>18 years old) ASA-classification between I-III, elective open primary umbilical hernia repair.

Exclusion criteria

Exclusion criteria: - primary umbilical hernia repair via scopic surgical technique. - emergency umbilical hernia repair - previous history of umbilical hernia repair. - simultaneous repair of other hernia defects - other surgical procedures performed during the primary umbilical hernia repair. - Patients with an ASA-classification >III. - Patients with any contraindications for an ultrasound guided bilateral rectus sheath block. - allergy for LA drugs - chronic treatment with analgesic drugs - previous history with the medical subspecialty of Pain Medicine. - previous history of a laparotomy or stoma. - no informed consent (IC) - impaired mental capacity for self- determination.

Design outcomes

Primary

MeasureTime frame
proportion of patients with a pain intensity of 3 or less, as assessed by the NRS

Secondary

MeasureTime frame
postoperative pain intensity as assessed by the NRS postoperative use of analgesics time to first dose of opiate analgesic the incidence of PONV the incidence of SAE related to USBRSB and LWI

Contacts

Public ContactB.P.C.M. van de Ven

Maxima Medisch Centrum Veldhoven

Email: d.vandeven@mmc.nlPhone (office): 040-888.50.30

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)